- Home
- UPWK vs VRDN Comparison
UPWK vs VRDN Comparison
Compare UPWK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPWK | VRDN |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | UPWK | VRDN |
|---|---|---|
| Price | $10.36 | $13.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $22.73 | ★ $35.46 |
| AVG Volume (30 Days) | 2.8M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $787,784,000.00 | $5,706,000.00 |
| Revenue This Year | $9.06 | $13.73 |
| Revenue Next Year | $13.57 | $279.00 |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $10.22 | $11.76 |
| 52 Week High | $22.84 | $34.29 |
Technical Indicators
Market Signals| Indicator | UPWK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 22.84 |
| Support Level | N/A | N/A |
| Resistance Level | $11.79 | $18.95 |
| Average True Range (ATR) | 0.52 | 0.61 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 10.79 | 2.62 |
Price Performance
Historical ComparisonAbout UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.